David I Kutler1, Krupa R Patel2, Arleen D Auerbach3, Jennifer Kennedy4, Francis P Lach4, Erica Sanborn4, Marc A Cohen1, William I Kuhel1, Agata Smogorzewska4. 1. Department of Otolaryngology-Head and Neck Surgery, New York Presbyterian Hospital/Weill Cornell Medical College, New York, New York, U.S.A. 2. Weill Cornell Medical College, The Rockefeller University, New York, New York, U.S.A. 3. Program in Human Genetics and Hematology, The Rockefeller University, New York, New York, U.S.A. 4. Laboratory of Genome Maintenance, The Rockefeller University, New York, New York, U.S.A.
Abstract
OBJECTIVES/HYPOTHESIS: To describe the management and outcomes of Fanconi anemia (FA) patients with head and neck squamous cell carcinoma. STUDY DESIGN: Cohort study. METHODS: Demographic information, prognostic factors, therapeutic management, and survival outcomes for FA patients enrolled in the International Fanconi Anemia Registry who developed head and neck squamous cell carcinoma (HNSCC) were analyzed. RESULTS: Thirty-five FA patients were diagnosed with HNSCC at a mean age of 32 years. The most common site of primary cancer was the oral cavity (26 of 35, 74%). Thirty patients underwent surgical resection of the cancer. Sixteen patients received radiation therapy with an average radiation dose of 5,050 cGy. The most common toxicities were high-grade mucositis (9 of 16, 56%), hematologic abnormalities (8 of 16, 50%), and dysphagia (8 of 16, 50%). Three patients received conventional chemotherapy and had significant complications, whereas three patients who received targeted chemotherapy with cetuximab had fewer toxicities. The 5-year overall survival rate was 39%, with a cause-specific survival rate of 47%. CONCLUSIONS: Fanconi anemia patients have a high risk of developing aggressive HNSCC at an early age. Fanconi anemia patients can tolerate complex ablative and reconstructive surgeries, but careful postoperative care is required to reduce morbidity. The treatment of FA-associated HNSCC is difficult secondary to the poor tolerance of radiation and chemotherapy. However, radiation should be used for high-risk cancers due to the poor survival in these patients. LEVEL OF EVIDENCE: 4.
OBJECTIVES/HYPOTHESIS: To describe the management and outcomes of Fanconi anemia (FA) patients with head and neck squamous cell carcinoma. STUDY DESIGN: Cohort study. METHODS: Demographic information, prognostic factors, therapeutic management, and survival outcomes for FA patients enrolled in the International Fanconi Anemia Registry who developed head and neck squamous cell carcinoma (HNSCC) were analyzed. RESULTS: Thirty-five FA patients were diagnosed with HNSCC at a mean age of 32 years. The most common site of primary cancer was the oral cavity (26 of 35, 74%). Thirty patients underwent surgical resection of the cancer. Sixteen patients received radiation therapy with an average radiation dose of 5,050 cGy. The most common toxicities were high-grade mucositis (9 of 16, 56%), hematologic abnormalities (8 of 16, 50%), and dysphagia (8 of 16, 50%). Three patients received conventional chemotherapy and had significant complications, whereas three patients who received targeted chemotherapy with cetuximab had fewer toxicities. The 5-year overall survival rate was 39%, with a cause-specific survival rate of 47%. CONCLUSIONS:Fanconi anemiapatients have a high risk of developing aggressive HNSCC at an early age. Fanconi anemiapatients can tolerate complex ablative and reconstructive surgeries, but careful postoperative care is required to reduce morbidity. The treatment of FA-associated HNSCC is difficult secondary to the poor tolerance of radiation and chemotherapy. However, radiation should be used for high-risk cancers due to the poor survival in these patients. LEVEL OF EVIDENCE: 4.
Authors: Yu-Hung Chen; Mathew J K Jones; Yandong Yin; Sarah B Crist; Luca Colnaghi; Robert J Sims; Eli Rothenberg; Prasad V Jallepalli; Tony T Huang Journal: Mol Cell Date: 2015-04-02 Impact factor: 17.970
Authors: I Garcia-Higuera; T Taniguchi; S Ganesan; M S Meyn; C Timmers; J Hejna; M Grompe; A D D'Andrea Journal: Mol Cell Date: 2001-02 Impact factor: 17.970
Authors: Kimberly A Rickman; Francis P Lach; Avinash Abhyankar; Frank X Donovan; Erica M Sanborn; Jennifer A Kennedy; Carrie Sougnez; Stacey B Gabriel; Olivier Elemento; Settara C Chandrasekharappa; Detlev Schindler; Arleen D Auerbach; Agata Smogorzewska Journal: Cell Rep Date: 2015-06-25 Impact factor: 9.423
Authors: Timothy M Chlon; Elizabeth E Hoskins; Christopher N Mayhew; Kathryn A Wikenheiser-Brokamp; Stella M Davies; Parinda Mehta; Kasiani C Myers; James M Wells; Susanne I Wells Journal: J Virol Date: 2014-07-16 Impact factor: 5.103
Authors: Andy Trotti; Lisa A Bellm; Joel B Epstein; Diana Frame; Henry J Fuchs; Clement K Gwede; Eugene Komaroff; Luba Nalysnyk; Marya D Zilberberg Journal: Radiother Oncol Date: 2003-03 Impact factor: 6.280
Authors: Daisy Klein Douwel; Rick A C M Boonen; David T Long; Anna A Szypowska; Markus Räschle; Johannes C Walter; Puck Knipscheer Journal: Mol Cell Date: 2014-04-10 Impact factor: 17.970
Authors: David I Kutler; Bhuvanesh Singh; Jaya Satagopan; Sat Dev Batish; Marianne Berwick; Philip F Giampietro; Helmut Hanenberg; Arleen D Auerbach Journal: Blood Date: 2002-09-26 Impact factor: 22.113
Authors: David I Kutler; Arleen D Auerbach; Jaya Satagopan; Philip F Giampietro; Sat Dev Batish; Andrew G Huvos; Andy Goberdhan; Jatin P Shah; Bhuvanesh Singh Journal: Arch Otolaryngol Head Neck Surg Date: 2003-01
Authors: Thomas H Beckham; Jonathan Leeman; Chiaojung Jillian Tsai; Nadeem Riaz; Eric Sherman; Bhuvanesh Singh; Nancy Lee; Sean McBride; Daniel S Higginson Journal: Head Neck Date: 2019-01-11 Impact factor: 3.147
Authors: Xueheng Zhao; Marion G Brusadelli; Sharon Sauter; Melinda Butsch Kovacic; Wujuan Zhang; Lindsey E Romick-Rosendale; Paul F Lambert; Kenneth D R Setchell; Susanne I Wells Journal: Clin Cancer Res Date: 2018-03-12 Impact factor: 12.531
Authors: Isabell Popp; Maqsood Punekar; Nick Telford; Stavros Stivaros; Kate Chandler; Meenakshi Minnis; Anna Castleton; Claire Higham; Louise Hopewell; D Gareth Evans; Anja Raams; Arjan F Theil; Stefan Meyer; Detlev Schindler Journal: BMC Med Genet Date: 2018-01-11 Impact factor: 2.103
Authors: Sonya Ruiz-Torres; Marion G Brusadelli; David P Witte; Kathryn A Wikenheiser-Brokamp; Sharon Sauter; Adam S Nelson; Mathieu Sertorio; Timothy M Chlon; Adam Lane; Parinda A Mehta; Kasiani C Myers; Mary C Bedard; Bidisha Pal; Dorothy M Supp; Paul F Lambert; Kakajan Komurov; Melinda Butsch Kovacic; Stella M Davies; Susanne I Wells Journal: Cell Stem Cell Date: 2020-11-23 Impact factor: 24.633